Anebulo Pharmaceuticals, Inc. (ANEB)

In February 2026, Anebulo Pharmaceuticals announced its board approved plans to voluntarily delist from The Nasdaq Capital Market and deregister with the SEC, causing the stock to plunge. In January 2026, the company completed an oversubscribed voluntary self-tender offer to purchase 300,000 shares of common stock at $3.50 per share. In December 2025, Anebulo announced its intent to commence a self-tender offer in lieu of a previously proposed reverse stock split, causing the stock to plunge. In November 2025, Anebulo reported its first-quarter fiscal year 2026 financial results and the first subjects being dosed in a Phase 1 intravenous study of selonabant and received a grant from NIDA. In September 2025, the company provided an update on its "going private" transaction and strategic alternatives and reported its fourth-quarter and fiscal year 2025 financial results. In July 2025, Anebulo approved a plan to terminate the registration of its common stock, which saw the stock price increase. Over the last 52 weeks, Anebulo Pharmaceuticals' stock has fluctuated between $0.43 and $3.42.

There is no readily available information to suggest significant demand seasonality for Anebulo Pharmaceuticals' products or services. The demand for its lead product candidate, selonabant, would be driven by the prevalence of acute cannabinoid intoxication and substance addiction, rather than seasonal factors.

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing treatments for acute cannabinoid intoxication (ACI) and substance addiction. Their primary product candidate, selonabant (ANEB-001), is a cannabinoid receptor antagonist designed to counteract the negative effects of cannabis toxicity. Selonabant has completed a Phase 2 clinical trial, and the company is prioritizing an intravenous formulation for pediatric patients.

Anebulo Pharmaceuticals, Inc. is headquartered in Lakeway, Texas, and operates exclusively within the United States.

Anebulo Pharmaceuticals' brand reputation has a consensus rating of "Reduce," lower than the average consensus rating of "Hold" for other "medical" companies. The company scored higher than 52% of companies evaluated by MarketBeat and ranked 512th out of 877 stocks in the medical sector based on its MarketRank™ score. Events impacting the company's reputation primarily revolve around its financial and corporate strategy decisions, such as the proposed reverse stock split, the tender offer, and the decision to delist from Nasdaq and deregister with the SEC.

Anebulo Pharmaceuticals, Inc. has 26 institutional owners and shareholders holding a total of 22,366,565 shares. Major institutional owners include 22nw, Lp, Nantahala Capital Management, LLC, Mangrove Partners, Vanguard Group Inc, and Morgan Stanley. Significant individual owners include Joseph Lawler and Aron English, and insiders collectively own 40.54% of the company.